A detailed history of Cutler Group LP transactions in Argenx Se stock. As of the latest transaction made, Cutler Group LP holds 75 shares of ARGX stock, worth $47,124. This represents 0.01% of its overall portfolio holdings.

Number of Shares
75
Previous 500 85.0%
Holding current value
$47,124
Previous $190,000 84.74%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 19, 2024

SELL
$356.95 - $413.29 $151,703 - $175,648
-425 Reduced 85.0%
75 $29,000
Q4 2023

Jan 18, 2024

BUY
$338.91 - $506.01 $127,091 - $189,753
375 Added 300.0%
500 $190,000
Q3 2023

Nov 07, 2023

BUY
$369.35 - $548.43 $46,168 - $68,553
125 New
125 $61,000
Q2 2021

Jul 19, 2021

SELL
$257.11 - $319.92 $334,243 - $415,896
-1,300 Closed
0 $0
Q1 2021

Apr 26, 2021

BUY
$268.3 - $380.31 $80,490 - $114,093
300 Added 30.0%
1,300 $358,000
Q4 2020

Jan 21, 2021

BUY
$248.13 - $308.36 $153,840 - $191,183
620 Added 163.16%
1,000 $294,000
Q3 2020

Oct 27, 2020

SELL
$215.51 - $272.51 $53,661 - $67,854
-249 Reduced 39.59%
380 $99,000
Q2 2020

Jul 22, 2020

SELL
$127.44 - $232.72 $85,512 - $156,155
-671 Reduced 51.62%
629 $141,000
Q1 2020

May 07, 2020

SELL
$108.83 - $165.23 $163,245 - $247,844
-1,500 Reduced 53.57%
1,300 $171,000
Q4 2019

Feb 06, 2020

BUY
$106.59 - $164.21 $255,816 - $394,104
2,400 Added 600.0%
2,800 $449,000
Q3 2019

Oct 28, 2019

SELL
$113.31 - $150.51 $29,913 - $39,734
-264 Reduced 39.76%
400 $45,000
Q3 2018

Nov 07, 2018

BUY
$75.5 - $96.63 $50,132 - $64,162
664 New
664 $50,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.